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Summary: (+)-4-Propyl-9-hydroxynaphthoxazine ( + PHNO) is a potent 
dopamine agonist that has been administered transdermally to four patients 
with Parkinson’s disease and “on-off ’ fluctuations. Skin patches of increasing 
size were used to treat these patients, who also received infrequent doses of 
oral levodopa if required. The effect of + PHNO was measured as an increased 
duration of action of individual levodopa doses. The clinical effect measured in 
this way was directly proportional to the plasma concentrations of +PHNO 
achieved. The plasma concentrations of +PHNO began to rise 4-6 h after 
patch application and reached a steady state by 24 h. The final plasma con- 
centration of +PHNO was proportional to the area of skin covered. Key 
Words: Parkinson’s disease-On-off fluctuations-Transdermal drug delivery- 
Dopamine agonist-( + )-4-Propyl-9-hydroxynaphthoxazine. 
For many patients with Parkinson’s disease, the development of “on-off’ fluc- 
tuations blights their otherwise good response to levodopa. This on-off syndrome 
consists of a variable and unpredictable response to regular oral levodopa and is 
now recognised as a major source of disability in patients with Parkinson’s disease 
who are receiving chronic levodopa therapy. Someone with a fully developed 
on-off syndrome exhibits the following features: (a) “off’ episodes characterised 
by typical parkinsonian rigidity, bradykinesia, and tremor (and sometimes dysto- 
nia, pain, panic, and depression) when levodopa fails to be effective; (b) “on” 
periods after a dose of levodopa during which there is a marked improvement in 
the features of parkinsonism but accompanied by peak-dose or diphasic chorei- 
form, dystonic, or stereotyped involuntary movements that may themselves be 
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disabling; (c) a tendency to switch suddenly between “off’ and “on” states in a 
way that cannot readily be predicted from the timing of individual levodopa doses 
or from the levels of levodopa in the plasma (1,2). 
It is known that such fluctuations can be significantly improved if plasma levo- 
dopa concentrations are kept constant, for example by means of an intravenous 
infusion of levodopa, and various attempts have been made to adapt this model of 
continuous dopaminergic stimulation for practical use. These have included the 
use of sustained-release levodopa tablets and trials using subcutaneous infusions 
of the dopamine agonists lisuride and apomorphine (3,4). 
( +)-4-Propyl-9-hydroxynaphthoxazine ( + PHNO), a novel and highly potent 
dopamine agonist, has recently been shown to reverse the parkinsonian deficits 
produced by I-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP) in marmosets 
and is effective given by oral and subcutaneous routes (5,6). In Parkinson’s dis- 
ease, + PHNO is effective in both mildly affected patients with a short duration of 
illness, and in more severely affected patients with on-off fluctuations (7,8). 
+PHNO would appear to be a good candidate for use in the control of on-off 
fluctuations if it could be administered in a continuous manner. 
It has been shown that +PHNO applied to the skin of rats is absorbed and 
produces systemic pharmacological effects (9). + PHNO is soluble in both aque- 
ous and lipid media and this is known to be an important physical property of 
drugs that are capable of transdermal absorption (10,ll). High potency, extensive 
first-pass metabolism, and the desire for continuous delivery are all features of 
+ PHNO that make it an ideal candidate for this method of administration. In view 
of this, skin patches containing + PHNO have been designed and manufactured 
with the intention of creating a transdermal continuous drug delivery system. The 
necessary technology has already been used in the management of conditions in 
which continuous therapy is of benefit and for which the necessary drugs have 
suitable physical and pharmacological properties. Examples are nitroglycerin for 
angina, clonidine for hypertension, scopolamine for motion sickness, and oestro- 
gens for postmenopausal hormone replacement therapy (12). 
We have investigated the use of + PHNO skin patches in patients with Parkin- 
son’s disease who have developed on-off fluctuations. The purposes of the study 
were to demonstrate whether skin patches were capable of delivering +PHNO 
into the systemic circulation and to assess the pharmacokinetics of this absorption 
route. 
METHODS 
Four patients with idiopathic Parkinson’s disease entered the study having 
given written informed consent. They were all levodopa-responsive but had de- 
veloped on-off fluctuations in their motor response to regular oral medication. 
(Details of the patients are shown in Table 1.) 
+PHNO was administered by applying circular skin patches to the anterior 
chest wall. The patches were capable of delivering + PHNO at a rate substantially 
greater than the rate of skin penetration. Two sizes of patch were available (2 and 
5 cm’) and these were used in various combinations so that larger areas of skin 
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TABLE 1. Details ofpatients 
Age Parkinson's Levodopa On-off Levodopa Other 
Patient (yr) disease therapy syndrome dose (mg/day)" medication 
1 45 12 12 9 950 Lithium 
2 39 8 8 4 950 Benzhexol 
3 54 22 17 9 2100 Lithium 
4 4s 9 6 5 1200 Benzhexol 
orphenadrine 
amantadine 
clomipramine 
trimipramine 
With a peripheral decarboxylase inhibitor. 
were covered on subsequent days. The areas used were 2,4 ,7 ,10 ,  IS, and 20 cm'. 
The patches were applied to a hairless area of chest wall skin (usually in the 
subclavicular or submammary regions) and they were stuck down with Microfoam 
tape (3M Company) so as to maintain close skin contact. Before patch application 
the patients washed and dried themselves gently with a towel, avoiding any degree 
of skin abrasion or trauma. They were asked not to use body lotions or talcum 
powder. Whenever possible patches were not applied to an area of skin that had 
been used on a previous day. 
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FIG. 1. The "on-off' charts for patients 1 and 2 comparing the effect of levodopa alone (normal 
response) and levodopa plus + PHNO (20-cm2 patch). Hour 0 was -8:OO a.m. 
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The first two patients had patches applied in the early morning ( -8 :OO a.m.) and 
these remained in place for up to 8 h. The second two patients had patches applied 
in the evening (-890 p.m.) and kept in place for up to 24 h. Patches were applied 
on alternate days so that there was always a 24-h washout period between doses. 
The patients received oral domperidone (60 mg/day) throughout the study. 
On each test day the patient took no antiparkinson medication after midnight so 
that they would expect to be “off’ on waking the next morning. The patients were 
monitored by bedside observation, which allowed an accurate on-off chart to be 
completed. This method of assessment is described in more detail elsewhere (13). 
The period of observation started at -8:OO a.m., which corresponded to hour 0 for 
patients 1 and 2, and to hour 12 for patients 3 and 4. If no effect from + PHNO was 
detected (i.e., if the patient did not switch “on”) then a single dose of levodopa 
was given and repeated if necessary every 4 h. During each study period blood 
samples were drawn for estimation of + PHNO concentration. At the end of each 
study period the patches were removed and the skin was examined for signs of 
local irritation or allergy. 
+PI-INO Assay 
Measurement of + PHNO plasma concentration was carried out using a radio- 
immunoassay, complete details of which will be published elsewhere. Antibodies 
0 2 4 6 8 1 0  1 2  
HOURS 
FIG. 2. Plasma concentrations of + PHNO in patients 1 and 2 after the application of 20-cm2 patches 
applied at hour 0 and removed at hour 8. -4- = Patient 1, -0- = patient 2, - - 0 - - = patient 
2 after patch removal. 
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were raised using 9-0-carboxypropyl-PHNO coupled to bovine serum albumin as 
the immunogen. The radioligand was 8-iodo(I-l25)-PHNO. A double antibody 
radioimmunoassay was established with a 1-ml total volume using antisera at a 
final dilution of up to 5 million, and a sensitivity of 0.3 pg per tube. Fifty percent 
inhibition of ligand binding occurred at -3 pg per tube. Biological samples were 
extracted at pH 9.2 with methyl t-butyl ether, and the drug was backextracted into 
0.01 N hydrochloric acid. Up to 0.2 ml of plasma was assayed, yielding a sensi- 
tivity of -2 pg PHNO per milliliter plasma. Recoveries were >90% and indepen- 
dent of concentration. 
RESULTS 
Patients 1 and 2 were monitored for between 4 and 8 h after application of 
patches of each size. In neither case was any clear effect seen until the maximum 
area of 20 cm2 was used. With this dose an effect was found that started between 
4 and 6 h after patch application, and this is illustrated by the relevant on-off 
charts (Fig. 1). Without + PHNO, a standard dose of levodopa (IS0 mg levodopa 
with carbidopa as Sinemet 110) produced a response (i.e. the patient turned “on”) 
that lasted for between 35 and 160 min (mean 103 min). The onset and termination 
of this response was abrupt and therefore its duration could be recorded with 
accuracy. For each patient this response can be compared with the effect of 
levodopa in combination with 20 cm2 + PHNO skin patches. In both patients an 
initial dose of levodopa gave rise to the normal length of “on” response. Patient 
1 switched “on” again spontaneously at 4% h (without further levodopa), and 
after a number of “on-off’ fluctuations stayed “on” for 6 h onwards. Brief 
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FIG. 3. The “on-off’ charts for patients 3 and 4 comparing the effect of 4 and 15-cm2 skin patches. 
Hour 12 was -8:OO a.m. (Key as for Figure 1 . )  
Movemenf Disorders, Vol. 4, No. 2. 1989 
134 R .  J .  COLEMAN ET AL. 
150- 
100- 
50 - 
periods could not be classified as either fully “on” or fully “off’ and these were 
called “intermediate.” Patient 2 required a second dose of levodopa, but its effect 
was prolonged far beyond what would normally have been expected. After the 
patches were removed, the response continued in both patients without further 
levodopa (in patient 1 for a further 3 h and in patient 2 for just more than 5 h). The 
+ PHNO plasma concentrations corresponding to these two doses are shown in 
Fig. 2. 
Patients 3 and 4 had patches applied at night and were monitored in the same 
way during the following day. None of the skin patches (from 4 to 20 cm’) turned 
these patients “on” when they awoke, so they were given levodopa. The patches 
of 4-cm2 size had little effect, but larger areas gave rise to longer “on” periods in 
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response to regular levodopa doses. Sample on-off charts (for 4 and 15 cm’) 
illustrate this (Fig. 3). With the 15-cm’ patch, patient 3 developed excessive 
chorea that became distressing at 16 h and so the patches were removed early. 
This patient did not subsequently receive 20 cm’. The + PHNO plasma concen- 
trations for patients 3 and 4 increased with larger patch area and they appeared to 
approach a steady state between 20 and 24 h (Fig. 4). A mean of the last’three 
levels obtained on each day (e.g., at 20, 22, and 24 h) provides an approximate 
“steady state” level and this appears to be governed by the total patch area used 
(Fig. 5). Similarly, the clinical response (calculated as length of time spent “on” 
per 100 mg of levodopa taken during the time of observation) can be related to the 
“steady state” +PHNO plasma concentration as already defined (Fig. 6).  Re- 
gression lines have been calculated; for each patient the correlations between 
patch area and plasma concentration and between plasma concentration and clin- 
ical response were statistically significant (Figs. 5 and 6) .  
No serious side effects were identified. Two patients experienced excessive 
chorea with the largest patch area used and this was similar to that sometimes 
induced by taking too much levodopa. In patient 2 the dyskinesias were accom- 
panied by anorexia and nausea and the intensity of these side effects reached a 
peak -2 h after the patches were removed. No skin imtation was observed. 
PATCH AREA (cm2) 
FIG. 5. The “steady state” plasma levels (mean of the last three values) is proportional to the area of 
patch used. Patient 3 (a): correlation coefficient = 0.968; f = 6.70; df = 4; p < 0.01. Patient 4 (m): 
correlation coefficient = 0.937; t = 4.66; df = 4; p C 0.05. 
Movement Disorders, Vol. 4. No. 2, 1989 
136 R .  J .  COLEMAN ET AL. 
50 
0 
50 100 150 200 250 300 
PLASMA PHNO CONCENTRATION (pglml) 
FIG. 6. The clinical response to levodopa (measured as minutes “on” per 100 mg levodopa) is 
proportional to the “steady state” + PHNO concentration. Patient 3 (0): correlation coefficient = 
0.92; t = 4.8; df = 4; p < 0.01. Patient 4 (W): correlation coefficient = 0.94; f = 6.0; df = 4; p < 0.005. 
DISCUSSION 
All four patients showed a response to +PHNO skin patches. In the first two 
patients, there was a clear difference between the response to levodopa alone and 
the response to levodopa with +PHNO (20 cm2). For both these patients the 
onset of action appeared to occur between 4 and 6 h after patch application. The 
plasma +PHNO IeveIs corresponded with this, starting to rise 3-4 h after appli- 
cation and continuing to rise until the time of removal. The clinical response of 
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both patients continued for several hours after removal and the side effects of 
patient 2 (chorea and nausea) reached maximum seventy at that time. In this 
patient, plasma concentrations continued to rise for 4 h after patch removal (Fig. 
2) although the unexpectedly large rise between hours 11 and 12 is unexplained. 
The delay between patch application and rising plasma levels represents the 
time taken for + PHNO to permeate the epidermis and reach the dermal capillar- 
ies. The skin and subcutaneous tissues appear to act as an additional “drug 
reservoir” between the patch and the systemic circulation so that the patch must 
saturate this compartment before the drug can begin to enter the bloodstream. 
+ PHNO retained in the skin continues to enter the circulation after the patches 
have been removed. 
The data obtained from the first two patients show that it takes longer than 8 h 
for + PHNO from these patches to achieve steady-state plasma levels. This sug- 
gests that the patch size required to produce an effect in less than 8 h (i.e., 20 cm2) 
would be in danger of overdosing these patients if left in place for a much longer 
period. In light of these results it was decided to monitor the effects of all patch 
sizes for 24 h in patients 3 and 4. No information was obtained from these two 
patients regarding the onset of + PHNO action. The plasma drug concentrations 
reached (or closely approached) a steady state between 18 and 24 h after patch 
application (Fig. 4). The final + PHNO levels were governed by the size of patch 
used and this confirms the notion that the area of skin covered represents the dose 
of drug administered. 
In the present study we have shown that +PHNO and levodopa may be used 
successfully in combination because + PHNO lengthens the patients’ response to 
individual levodopa doses. The degree of levodopa enhancement appears to be 
proportional to the + PHNO dose used and the plasma levels achieved. In these 
patients transdermal + PHNO did not produce a long continuous response with- 
out additional levodopa, although we have shown previously that oral +PHNO 
can switch patients “on” without levodopa (8). 
In light of these results, we are hopeful that continuous transdermal delivery of 
+PHNO will become a useful technique in the treatment of parkinsonian “on- 
off’ fluctuations. 
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